Samuel Blackman
Founder at DAY ONE BIOPHARMACEUTICALS, INC.
Net worth: 28 M $ as of 30/05/2024
Samuel Blackman active positions
| Companies | Position | Start | End |
|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/10/2018 | - |
| Founder | 31/10/2018 | - | |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | - | - |
| Founder | - | - |
Career history of Samuel Blackman
Former positions of Samuel Blackman
| Companies | Position | Start | End |
|---|---|---|---|
Mavupharma, Inc.
 Mavupharma, Inc. Pharmaceuticals: MajorHealth Technology Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA. | Corporate Officer/Principal | 31/08/2018 | 30/06/2019 |
| ARS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 31/07/2016 | 31/08/2018 |
| JUNO THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 31/05/2014 | 31/07/2016 |
Training of Samuel Blackman
| University of Illinois | Doctorate Degree |
Statistics
International
| United States | 7 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
DOT Therapeutics-2, Inc.
DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Health Technology |
Mavupharma, Inc.
Mavupharma, Inc. Pharmaceuticals: MajorHealth Technology Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA. | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson January 4, 2016 and is headquartered in Seattle, WA. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Samuel Blackman
- Experience